Prestige Consumer Healthcare INC 10-Q quarterly reports

Prestige Consumer Healthcare Inc. reported a 6.5% increase in total revenues for the three months ended June 30, 2026, driven by the acquisition of the OTC Wellness Business.

Prestige Consumer Healthcare reports a decline in Q3 net income and revenues, impacted by supply chain issues and a significant supplier loan write-off, despite strategic acquisitions.

Prestige Consumer Healthcare reported a decline in Q2 net income and revenue, while simultaneously announcing the acquisition of Pillar5 Pharma Inc. for $150 million.

Prestige Consumer Healthcare Inc. reported a 6.6% decline in total revenues for the first quarter of fiscal 2026, primarily due to supply constraints in its North American Eye & Ear Care segment, despite improved gross profit margins and strong operating cash flow.

Prestige Consumer Healthcare's Q3 2025 results show a slight revenue increase and continued efforts to manage economic uncertainties and debt.

Prestige Consumer Healthcare experienced a minor decrease in revenue for the second quarter of fiscal year 2025, while maintaining profitability.

Prestige Consumer Healthcare's first quarter of fiscal year 2025 saw a decrease in revenue compared to the same period last year, primarily due to supply chain issues and shifts in consumer purchasing patterns.

Prestige Consumer Healthcare saw a modest revenue increase in the third quarter of fiscal year 2024, despite ongoing economic challenges and supply chain issues.